AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,320.00GBp
31 Jul 2015
Change (% chg)

-- (--)
Prev Close
4,320.00p
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,492,335
52-wk High
4,931.68p
52-wk Low
4,019.00p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company's medicines include Crestor for... (more)

Overall

Beta: 0.56
Market Cap(Mil.): £54,589.32
Shares Outstanding(Mil.): 1,263.64
Dividend: 57.50
Yield (%): 4.22

Financials

  AZN.L Industry Sector
P/E (TTM): 72.28 37.25 40.68
EPS (TTM): 0.60 -- --
ROI: 2.91 16.52 15.78
ROE: 5.85 17.30 16.82
Search Stocks

Express Scripts excludes 20 more drugs from 2016 coverage

NEW YORK, July 31 - Express Scripts Holding Corp , the largest U.S. pharmacy benefit manager, said on Friday that it would exclude about 20 new medications in 2016 from insurance coverage, including two diabetes drugs and a weight loss drug.

31 Jul 2015

AstraZeneca beats profit forecasts, helped by external deals

LONDON - AstraZeneca revenue fell by a smaller-than-expected 7 percent in the second quarter, as income from selling rights to medicines offset generic competition to older drugs and a strong dollar. | Video

30 Jul 2015

BRIEF-AstraZeneca CEO says absolutely on track to meet mid and long-term targets

July 30 - AstraZeneca CEO Pascal Soriot told reporters: * CEO says absolutely on track to meet mid and long-term targets * CEO says externalisation deal-making will continue in H2 * CFO says externalisation deal-making revenues will be lower in H2 * For more news, please click here

30 Jul 2015

UPDATE 2-AstraZeneca beats profit forecasts, helped by external deals

* Q2 externalisation income $471 million (Adds details on drugs, latest shares)

30 Jul 2015

AstraZeneca beats profit forecasts, helped by external deals

LONDON, July 30 - AstraZeneca revenue fell by a smaller-than-expected 7 percent in the second quarter, as income from spinning off assets offset generic competition to older medicines and a strong dollar.

30 Jul 2015

AstraZeneca sells rare cancer drug to Sanofi for up to $300 million

LONDON - AstraZeneca , under pressure from falling sales of older drugs, is selling a medicine for a rare type of cancer to Sanofi as it continues a drive to raise cash by divesting certain assets.

27 Jul 2015

UPDATE 1-AstraZeneca sells rare cancer drug to Sanofi for up to $300 mln

LONDON, July 27 - AstraZeneca, under pressure from falling sales of older drugs, is selling a medicine for a rare type of cancer to Sanofi as it continues a drive to raise cash by divesting certain assets.

27 Jul 2015

European Factors-Futures lower as China woes spread

LONDON, July 27 - European equities were seen starting the week on a downbeat note, with futures trading lower after lingering fears over China's economic growth prospects and a sharp commodities sell-off rippling through global markets.

27 Jul 2015

AstraZeneca sells rare cancer drug to Sanofi for up $300 mln

LONDON, July 27 - AstraZeneca, under pressure from falling sales of older drugs, is selling a medicine for a rare type of cancer to Sanofi as it continues a drive to raise cash by divesting certain assets.

27 Jul 2015

BRIEF-Sanofi to acquire Caprelsa from Astrazeneca

* Sanofi and its subsidiary Henzyme said in a statement they have entered into a definitive agreement with AstraZeneca to acquire Caprelsa (vandetanib) Further company coverage:

27 Jul 2015

Earnings vs. Estimates

Search Stocks